ScreenerHero

ACIU AC Immune SA

NAS · US · Healthcare · Biotechnology · acimmune.com
2.550USD-0.78%Mkt Cap: 253.54M $P/E: —

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap253.54M USD
Enterprise Value179.30M USD
Revenue (TTM)17.51M USD
Gross Profit-28.41M USD
Net Income (TTM)-70.45M USD
Revenue/Share0.17 USD
Last Price2.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees90
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)4.23
PEG—
EV/EBITDA-4.22
EV/Revenue10.24
P/S14.31
P/B5.92
EPS (TTM)-0.50
EPS (Forward)0.60
52W Range
2.09524% of range4.000
52W High4.000 USD
52W Low2.095 USD
Profitability
Gross Margin-162.23%
Oper. Margin7.89%
EBITDA Margin-242.61%
Profit Margin-1971.65%
ROE-156.95%
ROA-45.67%
Growth
Revenue Growth1057.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.26M USD
CapEx (TTM)900.00K USD
FCF Margin-189.27%
FCF Yield-13.07%
Net Debt-71.25M USD
Net Debt/EBITDA1.68
Balance Sheet
Debt/Equity0.10
Current Ratio0.93
Quick Ratio0.89
Book Value/Sh0.43 USD
Cash/Share0.76 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.512 USD
Upside (mean)+233.8%
Target Range5.345 USD – 11.88 USD
5.345+233.8% to mean11.88
# Analysts4
Ownership
Shares Out.99.43M
Float39.19M
Insiders38.09%
Institutions24.43%
Short Interest
Short Ratio19.0d
Short % Float7.48%
Short % Out.3.50%
Shares Short3.48M
Short (prev mo.)3.41M
Technical
SMA 502.607 (-2.2%)
SMA 2002.810 (-9.2%)
Beta1.55
S&P 52W Chg16.45%
Avg Vol (30d)207.85K
Avg Vol (10d)257.58K
Technical Indicators
RSI (14)45.5
MACD-0.0097
MACD Signal0.0124
MACD Hist.-0.0221
BB Upper2.843 USD
BB Middle2.664 USD
BB Lower2.486 USD
BB Width13.42%
ATR (14)0.1504 USD
Vol Ratio (20d)1.19x